The proliferation of TF-1 cells treated with increasing concentrations of hOSM was assessed. After 48 hour treatment with hOSM, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
The purity of recombinant hOSM was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hOSM and staining overnight with Coomassie Blue.
Western blot analysis of extracts from TF-1 cells, untreated or treated with hOSM for 10 minutes, using Phospho-Stat3 (Tyr705) (DA37) XP® Rabbit mAb #9145 (upper) and Stat3 Antibody #9132 (lower).
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hOSM. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hOSM. All lots are greater than 98% pure.
Less than 0.01 ng endotoxin/1 μg hOSM.
The bioactivity of recombinant hOSM was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 50-500 pg/ml.
Based on amino acid sequencing, greater than 85% of recombinant hOSM starts at Aa26 (AAIGS) and has a calculated MW of 19,249. The remainder starts at Ile28 (IGSCS). DTT-reduced and non-reduced protein migrate as 32 kDa polypeptides. Lower mobility in SDS-PAGE is due to glycosylation.
Recombinant human Oncostatin M (hOSM) Ala26-Arg221 (Accession #NP_065391) was expressed in human 293 cells at Cell Signaling Technology.
Oncostatin M (OSM) is a member of the IL-6 family of cytokines that is produced primarily by activated T cells and macrophages (1,2). OSM induces fibroblast proliferation, inhibits tumor cell proliferation, and plays a role in immune regulation (2,3). Human OSM binds to two distinct receptor complexes, the OSMRβ/gp130 and LIFRβ/gp130 complexes (4). The ability of human OSM to bind to two receptors may explain the overlapping and distinct activities of human OSM and LIF. In contrast, Mouse OSM binds to the OSM receptor β (OSMRβ) which forms a heteromeric complex with the common IL-6 family receptor subunit, gp130 (4). OSM induces the activation the Jak2, Stat3, and Erk1/2 pathways (5).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.